Phase II trial of trimetrexate in untreated advanced gastric carcinoma - A Southwest Oncology Group study

Alexander Hantel, Catherine M. Tangen, John S. Macdonald, Stephen P Richman, Reginald P. Pugh, Theodore Pollock

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologie toxicities of grade ≥ 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/ 23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.

Original languageEnglish
Pages (from-to)155-157
Number of pages3
JournalInvestigational New Drugs
Volume12
Issue number2
DOIs
StatePublished - Jun 1 1994

Fingerprint

Trimetrexate
Stomach
Carcinoma
Adenocarcinoma
Appointments and Schedules
Confidence Intervals

Keywords

  • gastric adenocarcinoma
  • trimetrexate

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of trimetrexate in untreated advanced gastric carcinoma - A Southwest Oncology Group study. / Hantel, Alexander; Tangen, Catherine M.; Macdonald, John S.; Richman, Stephen P; Pugh, Reginald P.; Pollock, Theodore.

In: Investigational New Drugs, Vol. 12, No. 2, 01.06.1994, p. 155-157.

Research output: Contribution to journalArticle

Hantel, Alexander ; Tangen, Catherine M. ; Macdonald, John S. ; Richman, Stephen P ; Pugh, Reginald P. ; Pollock, Theodore. / Phase II trial of trimetrexate in untreated advanced gastric carcinoma - A Southwest Oncology Group study. In: Investigational New Drugs. 1994 ; Vol. 12, No. 2. pp. 155-157.
@article{130b46ef58b845ca8d446b203297ba57,
title = "Phase II trial of trimetrexate in untreated advanced gastric carcinoma - A Southwest Oncology Group study",
abstract = "Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4{\%} (95{\%} confidence interval 0-22{\%}). Hematologie toxicities of grade ≥ 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/ 23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.",
keywords = "gastric adenocarcinoma, trimetrexate",
author = "Alexander Hantel and Tangen, {Catherine M.} and Macdonald, {John S.} and Richman, {Stephen P} and Pugh, {Reginald P.} and Theodore Pollock",
year = "1994",
month = "6",
day = "1",
doi = "10.1007/BF00874448",
language = "English",
volume = "12",
pages = "155--157",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of trimetrexate in untreated advanced gastric carcinoma - A Southwest Oncology Group study

AU - Hantel, Alexander

AU - Tangen, Catherine M.

AU - Macdonald, John S.

AU - Richman, Stephen P

AU - Pugh, Reginald P.

AU - Pollock, Theodore

PY - 1994/6/1

Y1 - 1994/6/1

N2 - Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologie toxicities of grade ≥ 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/ 23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.

AB - Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologie toxicities of grade ≥ 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/ 23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.

KW - gastric adenocarcinoma

KW - trimetrexate

UR - http://www.scopus.com/inward/record.url?scp=0028153450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028153450&partnerID=8YFLogxK

U2 - 10.1007/BF00874448

DO - 10.1007/BF00874448

M3 - Article

C2 - 7860235

AN - SCOPUS:0028153450

VL - 12

SP - 155

EP - 157

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -